Welcome to the IMF data, including databases and platforms that have access to understandable and timely data, transforming lives by making economic and financial data findable, browsable, and usable.

Gilead and Novo Nordisk have announced their drug combinations for the fatty liver disease known as NASH checked out in a mid-stage proof-of-concept study. The companies said the trial met its ...